TTC Oncology LLC​

Founded in 2015 as an R&D, pre-revenue startup, TTC Oncology’s mission is to develop and bring to market a novel, small-molecule therapy to address unmet needs of breast cancer patients. TTC has a worldwide license from the University of Illinois at Chicago covering the therapy associated with modulation and mimicry of estrogen actions. Investigators are currently completing Phase I trials on TTC drug at four sites to establish drug safety.

Debra A. Tonetti, Ph.D.

Debra A. Tonetti, Ph.D.

Co-Founder of TTC-352 and TTC Oncology Director

Professor of Pharmacology, Interim Head, Department of Biopharmaceutical Sciences, College of Pharmacy, U of Illinois Chicago; 24 years experience as a cancer biologist. Trained in lab of Dr. V.C. Jordan (“Father of Tamoxifen”). Her lab focuses on the etiology and treatment of breast cancer, specifically on mechanisms of endocrine resistance. Her lab was the first to identify PKCα as a biomarker for tamoxifen resistance and developed preclinical xenograft models indicating PKCα is a predictive biomarker for estradiol-induced tumor regression. With Dr. Greg Thatcher, her lab developed the ShERPA, TTC-352, as a safer alternative to estradiol as characterized by a lack of uterine proliferation.

Gregory Thatcher, Ph.D.

Gregory Thatcher, Ph.D.

Co-Founder of TTC-352 and TTC Oncology Director

Hans Vahlteich Chair, Professor of Medicinal Chemistry, and co-leader of Translational Oncology and co-director of the NIA Predoctoral Training Program in Alzheimer’s Disease & Related Dementia, at U of Illinois Chicago; awarded Graduate Mentor and Innovator of the Year; completed SERC Research Fellowship at Oxford University. Over 140 scientific publications and has supervised more than 50 graduate students in chemical biology, chemical toxicology, and medicinal chemistry; research continuously funded by NIH since 2003.
Founded a start-up that took an Alzheimer’s drugs into clinical trials and sold for $35mm. Successfully translated academic drug discovery into investigational new drugs, with two new chemical entities currently in clinical trials for the treatment of metastatic breast cancer.

Arkadiusz Dudek MD Ph.D.

Arkadiusz Dudek MD Ph.D.

TTC Oncology’s Chief Medical Officer:

Professor of medicine at the Univ. of Illinois, and affiliated professor at U. of Minnesota; medical oncologist at HealthPartners Regions Hospital in St. Paul, MN.

He has more than 19 years’ experience in cancer clinical research, 20 years in clinical management of cancer, and 12 years in tumor biology, signal transduction, and cancer immunotherapy. Expertise is in design and execution of clinical trials for cancer therapy with a special interest in the development of novel cancer therapeutics. He has served 16 years in leadership positions in clinical trial offices at the Univ. of Minnesota and Univ. of Illinois. He chairs and manages a broad range of therapeutic or non-therapeutic clinical studies trials (phase 1 through phase 3, cooperative group, investigator-initiated, and industry-sponsored studies). He is author and co-author of more than 125 publications in peer-reviewed medical and research journals.

Arkadiusz Dudek MD Ph.D.

Robert P. Venuti

TTC Oncology’s Vice President for Clinical Studies:

Mr. Venuti has 32 years of clinical development and medical affairs experience, the last 25 years of which has been in the small/start-up drug development company arena. He has designed and managed multiple Phase 1, 2 and 3 clinical trial programs in the U.S. and Europe in multiple therapeutic areas, including oncology, cardiology (heart failure, angina, hypertension), gastroenterology (gastroparesis, inflammatory bowel disease, cirrhosis), dermatology (psoriasis, eczema), neurology and hematology/hemostasis. Most recently, Mr. Venuti was Senior Director, Clinical Development at Cardioxyl Pharmaceuticals.

Arkadiusz Dudek MD Ph.D.

Melody A. Pekarek

TTC Management

General Manager, responsible for overseeing and supporting work performed in the lab through clinical trials, for developing budgets and managing expenses, and for ensuring compliance of all development timelines.  She coordinates with TTC’s angel investor in Arizona.  

Our Clinical Studies Team

©2018 by TTC Oncology.